The stock has a 36-month beta value of 1.09. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATOS is 129.13M, and at present, short sellers hold a 6.27% of that float. On April 18, 2025, the average trading volume of ATOS was 649.73K shares.
ATOS) stock’s latest price update
The stock price of Atossa Therapeutics Inc (NASDAQ: ATOS) has jumped by 2.99 compared to previous close of 0.61. Despite this, the company has seen a gain of 5.66% in its stock price over the last five trading days. prnewswire.com reported 2025-04-10 that CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS).
ATOS’s Market Performance
Atossa Therapeutics Inc (ATOS) has experienced a 5.66% rise in stock performance for the past week, with a -16.17% drop in the past month, and a -26.40% drop in the past quarter. The volatility ratio for the week is 7.63%, and the volatility levels for the past 30 days are at 8.35% for ATOS. The simple moving average for the past 20 days is -5.25% for ATOS’s stock, with a -44.60% simple moving average for the past 200 days.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at -13.76% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.57% of loss for the given period.
Volatility was left at 8.35%, however, over the last 30 days, the volatility rate increased by 7.63%, as shares sank -12.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.67% lower at present.
During the last 5 trading sessions, ATOS rose by +5.66%, which changed the moving average for the period of 200-days by -48.08% in comparison to the 20-day moving average, which settled at $0.6578. In addition, Atossa Therapeutics Inc saw -34.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from Remmel H. Lawrence, who purchase 10,000 shares at the price of $0.70 back on Mar 26 ’25. After this action, Remmel H. Lawrence now owns 10,257 shares of Atossa Therapeutics Inc, valued at $7,000 using the latest closing price.
Stock Fundamentals for ATOS
The total capital return value is set at -0.39. Equity return is now at value -31.39, with -29.54 for asset returns.
Currently, EBITDA for the company is -31.35 million with net debt to EBITDA at 2.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.99.
Conclusion
To sum up, Atossa Therapeutics Inc (ATOS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
